Christian Klemt Sells 1,687 Shares of uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QUREGet Rating) CFO Christian Klemt sold 1,687 shares of the stock in a transaction that occurred on Thursday, June 16th. The shares were sold at an average price of $13.20, for a total transaction of $22,268.40. Following the transaction, the chief financial officer now owns 104,688 shares in the company, valued at $1,381,881.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

QURE stock traded up $1.10 on Tuesday, reaching $15.21. The company’s stock had a trading volume of 811,059 shares, compared to its average volume of 541,932. The business has a fifty day simple moving average of $15.12 and a two-hundred day simple moving average of $17.68. uniQure has a 12-month low of $12.52 and a 12-month high of $38.80. The firm has a market cap of $709.52 million, a PE ratio of 2.21 and a beta of 1.13. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 12.94.

uniQure (NASDAQ:QUREGet Rating) last announced its quarterly earnings results on Monday, May 2nd. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.33). uniQure had a return on equity of 54.85% and a net margin of 61.76%. The business had revenue of $1.79 million during the quarter, compared to analysts’ expectations of $51.23 million. As a group, research analysts anticipate that uniQure will post -3.54 earnings per share for the current fiscal year.

QURE has been the topic of a number of recent research reports. Stifel Nicolaus reduced their price target on shares of uniQure from $66.00 to $37.00 in a research report on Thursday, May 5th. UBS Group upgraded shares of uniQure from a “neutral” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Thursday, March 17th. Chardan Capital reduced their price target on shares of uniQure from $95.00 to $65.00 in a research report on Wednesday, March 30th. StockNews.com upgraded shares of uniQure from a “sell” rating to a “hold” rating in a report on Wednesday, June 8th. Finally, The Goldman Sachs Group cut their target price on shares of uniQure from $59.00 to $51.00 and set a “buy” rating on the stock in a report on Tuesday, May 24th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.43.

A number of hedge funds have recently made changes to their positions in the stock. Meeder Asset Management Inc. purchased a new position in uniQure during the first quarter valued at $27,000. First Quadrant L P CA purchased a new position in shares of uniQure in the 4th quarter worth about $37,000. PNC Financial Services Group Inc. increased its holdings in uniQure by 152.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,038 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,231 shares in the last quarter. Future Financial Wealth Managment LLC bought a new stake in uniQure in the 4th quarter worth about $43,000. Finally, Nisa Investment Advisors LLC bought a new stake in uniQure in the 4th quarter worth about $45,000. 81.35% of the stock is owned by institutional investors.

uniQure Company Profile (Get Rating)

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

Recommended Stories

Insider Buying and Selling by Quarter for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.